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https://doi.org/10.1016/j.stemcr.2019.09.011SUMMARYDespite the importance of understanding how variability across induced pluripotent stem cell (iPSC) lines due to non-genetic factors
(clone and passage) influences their differentiation outcome, large-scale studies capable of addressing this question have not yet been
conducted. Here, we differentiated 191 iPSC lines to generate iPSC-derived cardiovascular progenitor cells (iPSC-CVPCs). We observed
cellular heterogeneity across the iPSC-CVPC samples due to varying fractions of two cell types: cardiomyocytes (CMs) and epicar-
dium-derived cells (EPDCs). Comparing the transcriptomes of CM-fated and EPDC-fated iPSCs, we discovered that 91 signature genes
and X chromosome dosage differences are associated with these two distinct cardiac developmental trajectories. In an independent
set of 39 iPSCs differentiated into CMs, we confirmed that sex and transcriptional differences affect cardiac-fate outcome. Our study pro-
vides novel insights into how iPSC transcriptional andX chromosome gene dosage differences influence their response to differentiation
stimuli and, hence, cardiac cell fate.INTRODUCTION
Variability in human induced pluripotent stem cell (iPSC)
lines compromises their utility for regenerative medicine
and as a model system for genetic studies. This variability
affects iPSC differentiation outcome and, despite using
standardized differentiation protocols, results in the gener-
ation of samples with cellular heterogeneity (i.e., multiple
cell types are present within a given sample and the propor-
tions of cell types vary across samples). Previous large-scale
quantitative trait loci studies in iPSCs (DeBoever et al.,
2017; Kilpinen et al., 2017) have shown that genetic varia-
tion accounts for the majority of expression differences
between iPSC lines, but non-genetic (i.e., clonality and pas-
sage) factors also contribute to these differences (Panopou-
los et al., 2017b). Understanding how non-genetic tran-
scriptional differences between iPSC lines affect their
differentiation outcome is necessary to improve the ability
to generate cell types of interest.
Well-established small-molecule protocols for generating
iPSC-derived cardiovascular progenitor cells (iPSC-CVPCs)
(Lian et al., 2013) produce fetal-like cardiomyocytes, which
can undergo further specification as cells mature in culture
into various cardiac subtypes (atrial, ventricular, or nodal)
(Burridge et al., 2014). Based on variable cardiac troponin
T (cTnT) staining, the derived samples are known to display924 Stem Cell Reports j Vol. 13 j 924–938 j November 12, 2019 j ª 2019 Th
This is an open access article under the CC BY license (http://creativecommocellular heterogeneity (Dubois et al., 2011; Witty et al.,
2014), but the origin of the cTnT-negative non-myocyte
cells, and whether the same or different non-myocyte cell
types are consistently derived alongside cTnT-positive my-
ocytes across samples, have not previously been investi-
gated. The differentiation protocol is dependent onmanip-
ulation of WNT signaling, initially through activation of
the pathway by GSK3 inhibition, followed by inhibition
of the pathway by Porcupine (PORCN) inhibition (Mo
et al., 2013; Wang et al., 2013). An in-depth analysis of
the outcomes of independent differentiations of hundreds
of iPSC lines with different genetic backgrounds could pro-
vide insights into the origins of the non-myocyte cells, as
well as the extent to which non-genetic transcriptional dif-
ferences between iPSC lines contribute to the iPSC-CVPC
cellular heterogeneity.
Here, we used a highly standardized and systematic
approach to conduct 232 directed differentiations of 191
iPSC lines into iPSC-CVPCs. We characterized the cellular
heterogeneity of the iPSC-CVPC samples and showed
that only two distinct cell types were present, cardiomyo-
cytes (CMs) and epicardium-derived cells (EPDCs), which
varied in proportion across samples. As differentiation pro-
tocols to derive iPSC-CMs and iPSC-EPDCs primarily differ
by a step involving WNT inhibition to derive the former
but not the latter (Bao et al., 2016), we hypothesized thate Author(s).
ns.org/licenses/by/4.0/).
(legend on next page)
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the observed cellular heterogeneity could result from sub-
optimal WNT inhibition in subsets of cells across iPSC
lines. To test this hypothesis, we analyzed transcriptional
differences between iPSC lines that differentiated into
CMs and those that differentiated into EPDCs (e.g., iPSCs
with a CM fate or EPDC fate) and discovered 91 signature
genes associated with these two distinct cardiac differenti-
ation trajectories. These signature genes are involved in
differentiation, including the Wnt/b-catenin pathway,
muscle differentiation or cardiac-related functions, and
the transition of epicardial cells to EPDCs by epithelial-
mesenchymal transition (EMT). While the proportion of
variance explained by each of the signature genes varied
over three orders of magnitude, altogether they captured
approximately half of the total variance underlying iPSC
fate determination. Additionally, we show that variability
in X chromosome gene dosage (XactiveXactive versus Xactive
Xinactive versus XY) across iPSCs plays a role in cardiac-
fate determination. The association with X chromosome
gene dosage could in part be due to higher expression in
CM-fated iPSCs of chrXp11 genes, which encodes ELK1
and PORCN. Transcriptomic analysis of an independent
set of 39 iPSCs differentiated to the cardiac lineage using
a similar small-molecule protocol (Banovich et al., 2018)
confirmed our findings.RESULTS
iPSC-CVPCs Show Cellular Heterogeneity across
Samples
Togain insights intomolecularmechanisms thatcould influ-
ence variability in human iPSC differentiation outcome, we
employed a highly systematic approach (Figure S1) to differ-
entiate 191 pluripotent lines from 181 iPSCORE individuals
(Figure 1A and Table S1A) into iPSC-derived cardiovascular
progenitorcells (iPSC-CVPCs).Weuseda small-molecule car-
diac differentiation protocol used to derive cardiomyocytes
(Lian et al., 2015) followed on day 15 by lactate selection to
obtain pure cardiac cells (Tohyama et al., 2013). In total,Figure 1. Characterization of Cellular Heterogeneity in iPSC-CVPC
(A) Overview of the study design. Skin fibroblasts from 181 subjec
(191 lines, 232 differentiations). After WNT pathway activation at da
CMs if WNT signaling is successfully inhibited. If WNT signaling is n
differentiations, 193 were completed (day 25), and we observed that
(B) Distribution of %cTnT. Dashed red line represents the median val
(C–E) Immunofluorescence staining of (C) iPSC-CVPCs, (D) human atr
(F–H) Immunofluorescence staining of iPSC-CVPCs with markers DAPI,
showing (G) the presence of three populations: CMs (orange), EPDCs (b
samples (eight iPSC-CVPC lines and one ESC line) across the three clu
(I) Scatterplot showing the correlation between the %cTnT and the f
(J) Heatmap showing across all 34,905 single cells the expression ma
See also Figures S1 and S2.
926 Stem Cell Reports j Vol. 13 j 924–938 j November 12, 2019we conducted 232 differentiations, of which 193 (83.2%,
from 154 lines derived from 144 subjects) were completed,
i.e., reachedday25ofdifferentiation,while39 (from37 lines
derived from 37 subjects) were terminated prior to day 25
because they did not form a syncytial beating monolayer
(Tables S1B and S1C). The completed iPSC-CVPCs at day
25onaveragehadahighfractionofcells that stainedpositive
for cTnT (%cTnT, median = 89.2%; Figure 1B) and were pos-
itive by immunofluorescence for cardiac markers (Figures
1C–1F and S1); however, 15 lines had %cTnT <40%, indi-
cating that despite lactate selection, there was substantial
cellular heterogeneity within and across samples.Subset of Cells Shows Differential Response to WNT
Inhibition during Differentiation
To examine the cellular heterogeneity in the iPSC-CVPCs,
we performed single-cell RNA sequencing (scRNA-seq) on
eight samples with varying %cTnT values (42.2%–95.8%,
Tables S1E and S1F) and combined these data with scRNA-
seq from the H9 embryonic stem cell (ESC) line (total of
34,905 cells). We detected three distinct cell populations:
(1) population 1, 21,056 cells (60.3%); (2) population 2,
11,044 cells (31.6%); and (3) population 3, 2,805 cells
(8.1%, Figures 1G and S1; Table S1G). While populations 1
and2 comprised the eight iPSC-derived samples, population
3 almost exclusively included ESCs (97.7% of the 2,870
ESCs, Figures 1H and S2). The relative proportions of cells
that each of the iPSC-CVPC samples contributed to popula-
tion 1 versus population 2was strongly correlatedwith its%
cTnT value (r = 0.938, p = 1.893 104, t test; Figure 1I), sug-
gesting that population 1 was cardiomyocytes (CMs).
As CMs and epicardium lineage cells could both survive
lactate purification (Iyer et al., 2015; Tohyama et al.,
2013), we investigated whether the non-myocyte cells
composing population 2 were iPSC-EPDCs. We examined
the expression levels of 17 marker genes (Figure 1J) specific
for either CMs or EPDCs (including smooth muscle, fibro-
blasts, and genes involved in EMT) and two marker genes
for stem cells. Consistent with having a high number ofSamples
ts were reprogrammed to iPSCs and differentiated to iPSC-CVPCs
y 0 and its inactivation by IWP-2 at days 3–5, cells differentiate to
ot sufficiently inhibited, cells differentiate to EPDCs. Of the 232
different CVPC samples had different proportions of CMs and EPDCs.
ue.
ium, and (E) ventricle with markers DAPI, ACTN1, and CX43.
MLC2a+ and MLC2v+, and MLC2v+MLC2a+ (F). scRNA-seq UMAP plots
lue), and ESCs (green), and (H) the distribution of the nine analyzed
sters.
raction of cells in population 1 (CMs) for each of the nine samples.
rkers for stem cells, CMs, EMT, fibroblasts, and smooth muscle.
Figure 2. Transcriptomic Features of 180
iPSC-CVPC Samples
(A) Relative distributions of cell populations
estimated using CIBERSORT across 180 iPSC-
CVPC samples.
(B) Scatterplot showing the correlation be-
tween %cTnT (x axis) and the fraction of
population 1 in the iPSC-CVPCs calculated
using CIBERSORT (y axis).
(C) Heatmap showing the expression levels of
CM and EPDC marker genes (Figure 1J) in 180
iPSC-CVPC samples. Samples are colored
based on their fraction of population 1.
(D) PCA of the 1,000 genes with highest
variability from 184 iPSC samples, 180 iPSC-
CVPCs (triangles colored according to their
percentage of population 1), and samples
from GTEx (squares—left ventricle, right
ventricle, coronary artery, and aorta).cTnT-positive cells, population 1 expressed high levels of
CM-specific genes while population 2 expressed high levels
of EPDC-specific genes, and population 3 expressed high
levels of the stem cell markers POU5F1 and SOX2 (Fig-
ure S2). Of note, TNNT2 was expressed in some of the cells
in population 2, which is consistent with the strong, but
not absolute correlation between%cTnT value and fraction
of population 1 (Figure 1I), and previous studies showing
that some EPDCs express TNNT2 (Witty et al., 2014). These
results show that the small-molecule differentiation proto-
col followed by lactate purification resulted in the absence
of undifferentiated cells at day 25 and in the derivation of
two distinct cell populations, one of which expresses high
levels of CM markers, including TNNT2, NKX2-5, and
MEF2C (population 1), and the other which expresses
EPDC markers, including SNAI2, DDR2, VIM, and ACTA2
(population 2). Of note, the protocols for generating
iPSC-derived cardiomyocytes (iPSC-CMs) and iPSC-EPDCs
both involve activating the WNT signaling pathway (Bao
et al., 2016; Iyer et al., 2015) and have a shared intermedi-
ate mesoderm progenitor, but subsequent WNT inhibition
directs differentiating cells to iPSC-CMs and endogenous
levels of WNT signaling direct differentiating cells to
iPSC-EPDCs (Witty et al., 2014) (Figure 1A). Therefore,
our results suggest that iPSC-CVPC cellular heterogeneity
results from suboptimalWNT inhibition in a subset of cells
during differentiation, which then give rise to EPDCs.
iPSC-CVPCs Are Composed of Immature CMs and
EPDCs
To estimate the relative abundances of CM and EPDC cells
across our collection of iPSC-CVPC samples, we selected
the top 50 significantly overexpressed genes in each ofthe three scRNA-seq populations (150 genes in total,
p < 1013, edgeR, Table S2), obtained their expression levels
in bulk RNA-seq from 180 iPSC-CVPCs, and inputted these
values into CIBERSORT (Newman et al., 2015). We
observed that the proportions of each cell type varied
across the samples, although the iPSC-CVPCs tended to
have a greater fraction of CMs (84.8% ± 31.8%, Figure 2A)
than EPDCs (14.7% ± 32.0%), and essentially no stem cells
(0% ± 0.8%). Due to lactate selection, the small number
(67) of cells predicted to be ESCs may represent a distinct
differentiated cell type that is more similar to stem cells
than either CMs or EPDCs. The estimated fraction of CMs
and EPDCs in the iPSC-CVPCs was highly correlated with
%cTnT values (r = 0.927, p z 0, t test; Figure 2B), similar
to that observed in the analysis of the scRNA-seq data (Fig-
ure 1J). Finally, we showed that the iPSC-CVPCs with high
estimated CM or EPDC cellular fractions, respectively,
showed higher expression of CM markers (MEF2C, NKX2-
5, and ACTN2) and EPDC markers (ACTA2, TAGLN,
DDR2, and SNAI2, Figure 2C). These results indicate that
cellular heterogeneity across iPSC-CVPC samples largely
reflects different proportions of CMs and EPDCs.
To characterize the similarities between the iPSC-CVPC
transcriptomes and those of adult heart and artery samples,
we performed a principal-component analysis (PCA) using
the transcriptomes of 184 iPSCORE iPSCs, 180 iPSC-
CVPCs, and the 1,072 GTEx samples, including left
ventricle, atrial appendage, coronary artery, and aorta
(GTEx Consortium et al., 2017). We found that principal
component 1 (PC1) showed that iPSC-CVPCs correspond
to an intermediate state between the iPSCs and adult sam-
ples, suggesting that the derived CMs and EPDCs are
similar to immature cardiac cells (Figure 2D). PC2 dividedStem Cell Reports j Vol. 13 j 924–938 j November 12, 2019 927
(legend on next page)
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the samples based on cardiac lineage, namely the myocar-
dium (left ventricles and atrial appendages) and epicar-
dium (coronaries and aorta) (Perez-Pomares et al., 2016).
This analysis shows that derived iPSC-CMs and iPSC-
EPDCs lie on different cardiac developmental trajectories,
with the CMs corresponding to immature myocardium
and the EPDCs to immature epicardium.
iPSC Expression Signatures Affect Cardiac-Fate
Differentiation
Although all iPSCORE iPSCs have previously been shown
to be pluripotent (Panopoulos et al., 2017a), we sought to
determine whether transcriptomic differences existed be-
tween the iPSC lines that derived CVPCs containing CMs
versus those that gave rise to EPDCs (Figure 3A). Given
that all 180 iPSC-CVPCs contain both CMs and EPDCs
but at different ratios, we initially had to determine the
optimal CM/EPDC ratio to group the iPSC lines into those
that were CM-fated and those that were EPDC-fated.
Thresholds for 193 iPSC-CVPCs that completed differenti-
ation (harvested on day 25) were defined by the ratio of
CM/EPDC estimates from CIBERSORT (estimated %CM/
estimated %EPDC), while the 39 iPSC-CVPC differentia-
tions terminated prior to day 25 for not forming a beating
syncytium were assigned a CM/EPDC ratio of 0:100 (0%
CM/100% EPDC). We tested ten different CM/EPDC ratios
and found 116 autosomal genes that were differentially ex-
pressed at one or more of these ratios (Storey q value <0.1,
t test; Figures 3A and 3B; Table S3A). We observed that the
maximum number of the 116 genes (84, 72.5%) was differ-
entially expressed at the 30:70 (CM/EPDC) threshold and
55 of them (47.4%) had their strongest p value at this ratio
(Figure S3). For this reason, we determined that the 30:70
threshold was optimal, and grouped the iPSCs into 125
that were CM-fated (produced R30% CMs) and 59 thatFigure 3. iPSC Gene Signatures Associated with Cardiac Different
(A) Testing of ten CM/EPDC ratios (0:100 to 90:10, with 10% increm
CM-fated or EPDC-fated. For each threshold, the number of iPSC lines
(B) At the same thresholds indicated in (A), shown are the numbers
defined as CM-fated and EPDC-fated. The 30:70 threshold has the ma
(C) Volcano plot showing mean difference in expression levels for all
lines (x axis) and p value (y axis, t test). A positive difference indicat
indicates overexpression in EPDC-fated iPSCs. Significant genes are in
(D) Expression levels of the 91 signature genes in iPSCs as a function
Thick lines represent the average for 36 genes overexpressed in CM-f
iPSCs (blue).
(E) WNT/b-catenin pathway, muscle/cardiac related, or EMT/mesench
with nominal p values [p < 0.0015] indicated with an asterisk).
(F) GLM estimate (%CM population/expression) calculated for each s
(G) Bar plot showing the percentage of variability in iPSC fate that is e
show the 35 signature genes identified by L1 normalization that indep
do not have independent expression, the total sum of the percent va
See also Figures S3–S5.were EPDC-fated (produced >70% EPDCs; Figures 3B and
S4; Table S3B).
Of the 84 autosomal differentially expressed genes at the
30:70 (CM/EPDC) threshold, 35 were overexpressed in the
CM-fated iPSC lines and 49 were overexpressed in the
EPDC-fated iPSCs (Figures 3B–3D). These genes have func-
tions associated with three differentiation signatures: (1)
Wnt/b-catenin pathway (13 genes); (2) muscle and/or car-
diac differentiation (six genes); and (3) EMTand/or mesen-
chymal tissue development (six genes; Figure 3E and Table
S3C). We noted that seven borderline significant auto-
somal genes were also involved in one of the three repre-
sented signatures, and therefore added them to the final
list of differentially expressed genes. We investigated the
associations between the expression levels of the final list
of 91 signature genes in the 184 iPSCs and the fraction of
CMs in the resulting iPSC-CVPCs using linear regression,
and found significant associations for all genes (Figure 3F
and Table S3D). These results show that, independently
of the 30:70 (CM/EPDC) threshold used in the initial differ-
ential expression analysis, the expression levels of these
signature genes in the 184 iPSCs were significantly associ-
ated with differentiation outcome (e.g., CM or EPDC fate).
Signature Genes Capture a Large Fraction of the
Variance Underlying iPSC Fate Outcome
While the signature genes likely affected cardiac-fate deter-
mination, we did not expect each gene to contribute
equally. To explore the impact of each gene individually
on differentiation outcome, we calculated how much the
91 genes explained the variability underlying iPSC cell
fate. To quantify the percent of variance explained by
each gene (R2), we fit a generalized linear regression model
with a logit link function to each gene individually. We
found that the percentage of variance explained by eachiation Fate
ents) to determine the optimal threshold for defining an iPSC as
defined as CM-fated (orange) or EPDC-fated (blue) is shown.
of differentially expressed autosomal genes between the iPSC lines
ximum number of differentially expressed genes.
autosomal genes between CM-fated iPSC lines and EPDC-fated iPSC
es overexpression in CM-fated iPSCs, whereas a negative difference
dicated in red.
of the %CM population in their corresponding iPSC-CVPC samples.
ated iPSCs (orange) and for 55 genes overexpressed in EPDC-fated
ymal development signature genes (those differentially expressed
ignature gene. Mean and 95% confidence interval are shown.
xplained by each of the 91 signature genes. Bars highlighted in red
endently contributed to variance. Due to the fact that the 91 genes
riance explained is >1.
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individual gene varied over three orders of magnitude
(1.73 3 103 < R2< 8.97%; Figure 3G).
We next asked how these signature genes altogether
captured variability in differentiation fate. As several of the
signature genes had correlated expression levels (Figure S4),
to reduce overfitting in the regression analysis we included
an L1 norm penalty (i.e., LASSO regression) and used
10-fold cross-validation. We identified 35 genes that inde-
pendently contributed to variance and whose expression
levels collectively explainedmore thanhalf of the variability
in differentiation outcome across iPSC lines (average R2
from the 10-fold cross-validation = 0.512). Together these
data show that, while the proportion of variance explained
by each of the signature genes varied widely, altogether
they captured approximately half of the total variance
underlying differential iPSC fate outcome.
Inherited Genetic Variation Does Not Influence
Differentiation Outcome
We investigated whether genetic variation associated with
the expression of any of the signature genes contributed to
the differentiation outcome of iPSCs.We assessed the geno-
types of 8,620,159 variants in each iPSC line and per-
formed a genome-wide association study (GWAS) to inves-
tigate the association between genotype and the fraction of
CMs in the corresponding iPSC-CVPCs. We found that
none of these variants was associated with differentiation
outcome at genome-wide significance (p < 5 3 108;
Table S3E and Figure S5). To further examine the associa-
tion between genetic background and differentiation
outcome, we tested whether differentiations of different
iPSC clones from the same individual, and from members
of the same twin pair, were more likely to yield similar out-
comes compared with differentiations of iPSC clones from
individuals with different genetic backgrounds, and
observed similar distributions (Figure S5). While our power
to perform a GWAS was limited, this analysis shows that
the genetic background did not contribute to the variance
underlying iPSC differentiation outcome, indicating that
non-genetic (i.e., clonality and passage) factors played a
role in determining whether an iPSC line differentiated to
CMs or EPDCs.
GSEA Implicates ELK1 Targets and Genes on the X
Chromosome
To understand whether the transcriptomic differences
between CM-fated and EPDC-fated iPSCs were associated
with alterations in specific pathways or cellular function,
we performed a gene-set enrichment analysis (GSEA) on
9,808 MSigDB gene sets (Subramanian et al., 2005) using
the 15,228 expressed autosomal genes in the 184 iPSCs.
We identified 22 gene sets that were significantly associated
with iPSC fate, including enrichment in the 59 EPDC-fated930 Stem Cell Reports j Vol. 13 j 924–938 j November 12, 2019iPSCs for extracellularmatrix (Figure 4A and Table S4A) and
in the 125 CM-fated iPSCs for transcription factor activity
and ELK1 targets. To capture gene sets associated with
expression differences on the X chromosome, we per-
formed differential expression and GSEA on 113 female
iPSC lines (87 CM-fated and 26 EPDC-fated). The two
most significant gene sets were loci locatedwithin chrXp11
and chrXp22 (Figure 4B). Notably, the chrXp11 locus en-
codes both ELK1 and PORCN, whose protein product
(Porcupine) is targeted for WNT inhibition in CM differen-
tiation protocols but not EPDC differentiation protocols
(Mo et al., 2013; Wang et al., 2013) (Figure 4B). The
chrXp22 locus includes the majority of genes (52/99,
52.5%) that are known to escape chromosome X inactiva-
tion (Tukiainen et al., 2017), and thus may potentially
have varying X-linked gene dosage across female iPSCs.
Overall, GSEA shows that genes differentially expressed
between CM-fated and EPDC-fated iPSCs are involved in
a variety of pathways, including ELK targets, and are poten-
tially associated with the X chromosome activation status.
Sex Is Associated with iPSC Differentiation Outcome
To identify other iPSC factors potentially associated with
differentiation outcome, we examined three characteristics
of the 181 subjects in our study (sex, ethnicity, and age) and
passage of the iPSCs at day 0. Analyzing the 125 CM-fated
and 59 EPDC-fated iPSC lines with a general linear model,
we found no association between differentiation outcome
and age or ethnicity (p > 0.8; generalized linear model
[GLM], Z test; Figure S6 and Table S4B), but observed a sig-
nificant association with sex (p = 2.573 105, GLM, Z test;
Figure 4C) and a trend for iPSC passage at day 0 (p = 0.069,
GLM, Z test; Figure S6). These data suggest that iPSCs
derived from female subjects and iPSCs with higher pas-
sages at day 0 had an increased predisposition for the CM
fate. Furthermore, considering only the 191 completed dif-
ferentiations (day-25 iPSC-CVPC samples), we found that
iPSC-CVPC samples derived from female subjects
compared with those derived from males had significantly
higher %cTnT values (mean = 83.0% and 77.7%, respec-
tively, for females and males; p = 6.0 3 104, Mann-Whit-
ney U test; Figure S6) and a higher fraction of CMs
(p = 6.463 104,Mann-Whitney U test). These results indi-
cate that iPSCs derived from female subjects and, to a lesser
extent, iPSCs that have spentmore time in cell culture have
a greater inherent predisposition to differentiate toward
the CM lineage.
Female iPSCs with X Chromosome Reactivation
Associated with CM Fate
Given the observation that female iPSCs have a greater po-
tential to differentiate to CMs and that differential expres-
sion of chrXp11 genes were associated with differentiation
Figure 4. X Chromosome Gene Dosage
Plays a Role in Cardiac Differentiation Fate
(A) GSEA results. For each gene set,
log10(q value) is shown. Positive values
correspond to gene sets enriched in CM-fated
iPSCs, whereas negative values correspond to
EPDC-fated iPSCs. For autosomes all iPSCs
were included (top), for the chromosome X
only the 113 female iPSCs were analyzed
(bottom). Storey q value was used to adjust
for multiple testing hypothesis; q values
<0.05 were considered significant.
(B) Cartoon showing the positions of differ-
entially expressed loci on chromosome X and
of ELK1 and PORCN.
(C–F) Bar plot (C) showing the associations
between sex and differentiation outcome
(orange: iPSC-CVPC samples with CM fraction
>30%; blue: with EPDC fraction >70%). p
values were calculated using Z test. Density
plots showing the differences in allelic
imbalance fraction between: (D) autosomal
genes (pink) and chrX genes outside of the
pseudoautosomal region (maroon) in female
iPSCs; (E) chrX genes in female CM-fated
(light orange) and EPDC-fated (light blue)
iPSCs; (F) chrX genes in female day 25 iPSC-
CVPC samples with CM fraction >30% (orange)
and EPDC fraction >70% (blue). p values in
(D) to (F) were calculated using the Mann-
Whitney U test.
See also Figure S6.outcome, we asked whether variation in X chromosome
inactivation (Xi) and activation (Xa) state across female
iPSC lines was associated with CM or EPDC fate. Using
RNA-seq data generated from the 113 female iPSCs, we
evaluated allele-specific effects (ASE) of X chromosome
and autosomal genes (Table S4C). We defined the strength
of ASE for each gene as the fraction of RNA transcripts that
were estimated to originate from the allele with higher
expression (hereafter referred to as ‘‘allelic imbalance frac-
tion’’ [AIF]). We observed that AIF in autosomal genes
was close to 0.5, indicating that both alleles were equallyexpressed (Figure 4D), while AIF on the X chromosome in
iPSCs tended to be bimodal, with some genes showing
monoallelic expression (AIF 1.0; XaXi) and others
showing biallelic expression (AIF0.5; XaXa).We observed
that AIFwas less in the 87CM-fated female iPSCs compared
with the 26 EPDC-fated female iPSCs (p = 0.011, Mann-
Whitney U test; Figure 4E) and that this difference in AIF
became even more pronounced in the corresponding
derived iPSC-CVPC samples (p = 4.813 106, Mann-Whit-
ney U test; Figures 4F and S7). These findings show that in
iPSCs, differential chromosome XaXi status as well asStem Cell Reports j Vol. 13 j 924–938 j November 12, 2019 931
Figure 5. Validation of Association between iPSC Gene Signatures, Sex, and Differentiation Outcome
(A) Schematic depicting differences between the iPSCORE and Yoruba iPSC samples.
(B) Estimated fractions of CMs and EPDCs for 13 Yoruba iPSC-CM samples from RNA-seq using CIBERSORT (two iPSC-CMs did not have
RNA-seq).
(C) Scatterplot showing the correlation between %cTnT and the fraction of cells in population 1 for 13 Yoruba iPSC-CM samples.
(D) Box plots showing the distribution of estimated fraction of cells in population 1 in females and males.
(E) Box plots showing correlation of gene expression in all 184 iPSCORE iPSCs with RNA-seq (purple), 34 Yoruba iPSCs with RNA-seq used for
differentiation, and the pairwise comparison of the Yoruba iPSCs against the iPSCORE iPSCs (gray).
(F) Volcano plot showing mean difference in expression levels for all autosomal genes between 14 Yoruba iPSC lines that were successfully
differentiated and 125 iPSCORE iPSC-CM-fated lines and p value (y axis, t test). Significant genes are indicated in red.
(G) Smooth color density scatterplot showing gene-expression differences between iPSCs with different fates in 184 iPSCORE iPSCs to the
expression differences between iPSCs with different outcomes in Yoruba iPSCs (14 successful versus 20 terminated) (y axis). A positive
difference indicates shared overexpression of genes between CM-fated iPSC in iPSCORE and successfully differentiated iPSC in the Yoruba
set, whereas a negative difference indicates shared overexpression of genes between EPDC-fated iPSC in iPSCORE and terminated iPSC in
(legend continued on next page)
932 Stem Cell Reports j Vol. 13 j 924–938 j November 12, 2019
altered gene expression in chrXp22 and chrXp11 contrib-
utes to differences in cardiac-fate differentiation outcome.
Sincewe observed differences in X chromosome reactiva-
tion state between CM-fated and EPDC-fated female iPSCs,
we next asked whether the two GSEA X chromosome-asso-
ciated intervals (chrXp22 and chrXp11; Figure 4A) showed
corresponding allelic imbalance trends. We plotted AIF dif-
ferences, whereby a positive AIF difference indicates X
chromosome reactivation in the 26 EPDC-fated iPSCs and
a negative effect in the 87 CM-fated iPSCs (Figure S6). We
observed that distinct regions across the X chromosome
were differentially eroded in the EPDC-fated versus CM-
fated iPSCs. In particular, chrXp22 showed X reactivation
in CM-fated iPSCs (p = 6.31 3 103, Mann-Whitney U
test), with both escape (p = 0.020, Mann-Whitney U test)
and non-escape genes (p = 0.023, Mann-Whitney U test)
showing evidence of reactivation (Figure S6). As chrXp22
contains more than half of the escape genes on the X chro-
mosome, this observation confirms that increased X reacti-
vation in CM-fated iPSCs results in increased expression of
both escape and non-escape genes. As GSEA identified
genes on chrXp11 to be overexpressed in CM-fated iPSCs,
the lack of X reactivation in this interval (p = 0.28,
Mann-Whitney U test) suggests that alternative regulatory
mechanismsmay also alter gene-expression levels on the X
chromosome.Overall, these results suggest that differential
X chromosome reactivation as well as other mechanisms
underlying altered regulation of X chromosome and auto-
somal genes contribute to iPSC cardiac lineage fate
determination.
Independent iPSC-CM Derivation Study Validates
Findings
To assess the generalizability of our findings, we examined
an independent collection of 39 iPSCs (Banovich et al.,
2018) reprogrammed using an episomal plasmid from
Yoruba lymphoblastoid cell lines (Figure 5A and
Table S5). Differentiation of these lines resulted in the suc-
cessful derivation of 13 iPSC-CMs (%cTnT range at day 32:
40–96.9), whereas 24 were terminated on or before day 10
due to the fact that they did not form a beating syncytium.
To examine whether the successfully derived Yoruba iPSC-
CMs showed the presence of EPDCs, we used RNA-seq data
and CIBERSORT to estimate cellular compositions and
observed variable relative distributions of CM and EPDC
populations (Figure 5B). Consistent with our iPSCORE
iPSC-CVPC samples, the estimated CM population frac-the Yoruba set. Of the 91 signature genes that were differentially exp
significant expression differences in the same direction in the Yorub
(H) Bar plot showing that the eight iPSCORE differentially expressed
same direction (e.g., overexpressed or down regulated) in the Yoruba
See also Figure S7.tions were significantly correlated with %cTnT values
(r = 0.81, p = 7.94 3 104, t test; Figure 5C). To understand
whether the CMs and EPDCs appear at the same time dur-
ing differentiation, we analyzed data generated the from
the Yoruba lines at four time points (Strober et al., 2019)
and observed that both cardiac lineages are typically pre-
sent by day 5 and that the ratio of these two cardiac cell
types remains relatively stable past day 10 (Figure S7).
Finally, Yoruba iPSC-CMs derived from females tended to
have an increased percentage of CMs compared with those
derived from males (Figure 5D). These observations show
that the Yoruba iPSCs and derived cardiac cells could be
used to investigate the generalizability of the associations
that we had observed between transcriptomic differences
in iPSCs and cardiac-fate differentiation outcome.
As several factors (Figure 5A) were different between the
iPSCORE iPSC and Yoruba iPSC sets (i.e., different reprog-
ramming method, genetic backgrounds, and donor cell
types), we expected that there would be significant differ-
ences between their transcriptional profiles. We initially
analyzed how correlated gene expressionwas: (1) within iP-
SCORE iPSCs; (2) within Yoruba iPSCs; and (3) between all
pairwise comparisons of the iPSCs in these two different
collections (Figure 5E). We observed high correlations of
gene expression across iPSCs within each collection; how-
ever, the correlation between samples from different
studies was significantly decreased, indicating that the
two sets have significant genome-wide gene-expression dif-
ferences. We next examined differential gene expression
between the CM-fated iPSCORE iPSC and Yoruba iPSCs
that successfully differentiated into iPSC-CMs (Figure 5F),
and observed that the majority of genes (69.6% with q
value <0.10) were significantly differentially expressed be-
tween the two iPSC sets. These results show that there are
strong batch effects on gene expression between the
iPSCORE and Yoruba iPSC lines.
We investigated whether, despite the strong batch effects
on gene expression between iPSCORE and Yoruba iPSCs,
we could detect inherent transcriptional differences
affecting cardiac-fate determination that were shared be-
tween the iPSC sets. Given the relatively small size of the
Yoruba study, there was insufficient power to detect tran-
scriptional differences between the lines with different dif-
ferentiation outcomes (successfully completed versus
terminated). Therefore, for each gene, we compared the
mean expression differences between iPSCs with different
cardiac-fate outcomes in iPSCORE (CM fate minus EPDCressed in the iPSCORE iPSCs based on cell fate, eight had nominally
a iPSC set (shown in red).
genes in (G) with nominal significant expression differences in the
iPSCs are greater than random expectation.
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Figure 6. iPSC Characteristics that Influence Their Cardiac-Fate
Determination
Cartoon showing iPSC characteristics that influence their cardiac-
fate determination, including: (1) the expression levels of 91 genes
grouped into three gene signature classes (WNT/B-catenin
pathway, cardiac development genes, and genes involved in EMT);
(2) sex: female iPSCs are more likely to differentiate to CMs than
males; and (3) X chromosome activation state: female iPSCs that
have activated both X chromosomes (XaXa) are more likely to
differentiate to CMs.fate) to the expression differences between iPSCs with
different differentiation outcomes in the Yoruba set
(successfully completed minus terminated; Figure 5G).
We observed a small but significant correlation (r =
0.0299, p = 4.71 3 104, t test) between genes that were
differentially expressed in the iPSCORE iPSCs and those
that were differentially expressed in the Yoruba iPSCs.
Furthermore, we specifically examined the 91 signature
genes significantly associated with iPSCORE iPSC cardiac-
fate outcome and found eight with nominally significant
expression differences in the same direction (e.g., overex-
pressed or downregulated) in the two sets of iPSCs (Fig-
ure 5G), which is 2.5 times more than random expectation
(p = 0.012, Fisher’s exact test; Figure 5H). These data suggest934 Stem Cell Reports j Vol. 13 j 924–938 j November 12, 2019that the iPSCORE iPSCs and Yoruba iPSCs shared transcrip-
tional differences that affected cardiac-fate differentiation
outcome.DISCUSSION
While previous directed cardiac differentiation studies
have observed the emergence of both cardiomyocytes
and a non-contractile cell population, the origin of these
non-contractile cells, and whether the same or different
non-myocyte cell types are present across iPSC-CVPC sam-
ples, has not previously been addressed. We showed that
two distinct cell types were present in 154 iPSC-CVPC sam-
ples derived from iPSCs in iPSCORE. One of the derived cell
types were CMs, characterized by high expression levels of
cardiac-specific genes, and the other derived cell type was
EPDCs, characterized by high expression of marker genes
for EMT, smooth muscle, and fibroblasts. We found the
same two cardiac cell types present in iPSC-CMs derived
from an independent collection of 39 Yoruba iPSCs, both
ofwhichwere typically present by day 5, and their ratios re-
mained relatively stable past day 10 (Banovich et al., 2018;
Strober et al., 2019). A recent study showed that adding hu-
man ESC-derived epicardial cells to cardiomyocyte grafts
in vivo improves transplantation efficacy, as it increases
contractility, myofibril structure, and calcium handling
and decreases tissue stiffness (Bargehr et al., 2019). Our
findings suggest that the generation of EPDCs during
iPSC-CM differentiation may enhance the structure of
the derived CMs and that to efficiently use iPSC-CVPCs
in a clinical setting, future studies may need to optimize
the relative proportions of CMs and EPDCs that maximize
their transplantation efficiency.
The scale of our study, 232 attempted differentiations of
191 iPSC lines into the cardiac lineage, provided the power
to develop a framework to identify non-genetic transcrip-
tional differences in iPSCs that influence their cardiac dif-
ferentiation outcome. To minimize the factors that might
influence differentiation outcome, such as the optimal
cell confluence at which to start differentiation, we attemp-
ted to standardize all steps in the differentiation protocol in
order to remove subjective decisions and diminish experi-
mental differences between samples. We identified 91
signature genes whose differential expression was associ-
ated with differentiation outcome and showed that many
of these genes are involved in cardiac development,
including the Wnt/b-catenin pathway, muscle differentia-
tion or cardiac-related functions, and the transition of
epicardial cells to EPDCs by EMT (Figure 6). Many of the
transcriptomic differences between iPSCORE iPSCs with
CM fates versus those with EPDC fates may be due to aber-
rant epigenetic landscapes resulting from a combination of
the reprogramming method (Sendai virus) and cell of
origin (fibroblasts). However, given that the Yoruba iPSCs
were reprogrammed using a different method (episomal
plasmid) and cell of origin (lymphoblastoid cell lines
[LCLs]) and yet the iPSCORE and Yoruba iPSCs shared
gene-expression differences associated with cardiac lineage
outcome, it is likely that our findings will likely be general-
izable to other collections of iPSCs. We hypothesize that
the signature genes associated with cardiac lineage
outcome will vary across iPSC collections and depend on
the reprogramming method and cell type of origin, but
will largely be involved in the same pathways identified
in this study.
We observed that variability across iPSCs on X chromo-
some gene dosage (XaXa versus XaXi versus XY) played a
role in cardiac lineage fate (Figure 6). While human iPSCs
are known to have only partial XaXa (Barakat et al., 2015;
Kim et al., 2014), we identified two loci (chrXp11 and
chrXp22) encoding genes whose expression levels are asso-
ciated with two distinct cardiac differentiation trajectories
(CMs versus EPDCs). The higher expression of chrXp11
genes in CM-fated iPSCs may at least in part be due to
fact that ELK1 and PORCN are both encoded in this inter-
val, as the protein product of PORCN (Porcupine) is in-
hibited by IWP-2 during CM differentiation (Mo et al.,
2013) but not during EPDC differentiation (Bao et al.,
2016; Iyer et al., 2015; Witty et al., 2014) (some EPDC pro-
tocols inhibit Porcupine but then reactivate the WNT
pathway at a later time point [Guadix et al., 2017; Paik
and Wu, 2017; Zhao et al., 2017]). Furthermore, we found
that ELK1 targets are overexpressed in CM-fated iPSCs,
which is consistent with previous studies showing that
knockdown of ELK1 in immortalized human bronchial
epithelial cells, small airway epithelial cells, and luminal
breast cancer cell line (MCF-7) is associated with increased
EMT (Desai et al., 2017; Tatler et al., 2016). Also consistent
with ELK1 playing a role in the association betweenX chro-
mosome dosage and differentiation outcome is a previous
study showing that ELK1 overexpression or downregula-
tion, respectively, mimics the phenotypes of XaXa or
XaXi PSCs (Bruck et al., 2013). Of note, atrioventricular
septal defects occur in 20% of individuals with Down
Syndrome (DS), and have a higher prevalence in female
DS patients (Diogenes et al., 2017). Given that EPDCs
play an essential role in septal formation (Gittenberger-de
Groot et al., 2000), our study suggests that future work
should investigate the extent to which X chromosome
gene-expression levels are altered in cardiomyocytes from
individuals with DS, and whether this is associated with
the formation of fewer EPDCs.
Overall, our study suggests that expression differences of
91 signature and X chromosome genes result in the
iPSCORE iPSC lines having differential propensities torespond to WNT inhibition during differentiation, and
consequently are fated to produce iPSC-CVPC samples
with different proportions of CMs and EPDCs. As iPSCs
in the iPSCORE collection have passed standard quality
checks to confirm their pluripotency and genomic integ-
rity (Banovich et al., 2018; Panopoulos et al., 2017a), these
transcriptomic expression differences associated with car-
diac lineage outcome are not detected using current quality
metrics. In conclusion, our findings suggest that to derive
human iPSC lines that respond similarly in differentiation
protocols, it may be necessary to improve reprogramming
methods such that the transcriptome and X chromosome
activation state is fully reset to the naive state, and incorpo-
rate inactivation of one of the X chromosomes in female
lines as an early step in differentiation protocols.EXPERIMENTAL PROCEDURES
Please refer to Supplemental Experimental Procedures for detailed
methods.Subject Information and Whole-Genome Sequencing
Individuals (108 females and 73males) were recruited as part of the
iPSCORE project (Panopoulos et al., 2017a) and included 7 MZ
twin pairs, members of 32 families (2–10 members/family), and
71 singletons and were of diverse ancestries. Subject descriptions
including subject sex, age, family, ethnicity, and cardiac diseases
were collected during recruitment. As previously described (DeBo-
ever et al., 2017), we generated whole-genome sequences from the
blood or skin fibroblasts of the 181 subjects on the HiSeqX
(Illumina; 150-bp paired end). The recruitment of these individ-
uals was approved by the Institutional Review Boards of the Uni-
versity of California, San Diego and The Salk Institute (project
no. 110776ZF).iPSC Derivation and Somatic Mutation Analysis
As previously described, we reprogrammed fibroblast samples us-
ing non-integrative Cytotune Sendai virus (Life Technologies),
and the 191 iPSCs (seven subjects had two or more clones each)
were shown to be pluripotent and to have high genomic integrity
with no or low numbers of somatic copy-number variants (CNVs)
(D’Antonio et al., 2018; Panopoulos et al., 2017a).Large-Scale Derivation of iPSC-CVPC Samples
To generate iPSC-derived cardiovascular progenitors (iPSC-
CVPCs), we used a small-molecule cardiac differentiation protocol
(Lian et al., 2013). The 25-day differentiation protocol consisted of
five phases (Figure S1A); the optimizations for each step are
described in the Supplemental Experimental Procedures.Flow Cytometry
On day 25 of differentiation, iPSC-CVPCs were stained with cTnT
antibody, acquired using fluorescence-activated cell sorting and
analyzed using FlowJo V10.2.Stem Cell Reports j Vol. 13 j 924–938 j November 12, 2019 935
Immunofluorescence Analysis of iPSC-CVPCs
Immunofluorescence was assessed in five iPSC-CVPC lines. Live
frozen iPSC-CVPC harvested on day 25 were thawed, plated
for 5 days, fixed, permeabilized, and incubated with antibodies
(Table S1D).
Generation of RNA-Seq Data
For gene-expression profiling of iPSCs, we used RNA-seq data from
184 samples (cell lysates collected between passages 12 and 40). For
gene-expression profiling of iPSC-CVPCs, we generated RNA-seq
data from 180 samples at day 25 of differentiation. All RNA-seq sam-
ples were generated and analyzed using the same pipeline to obtain
transcripts per million base pairs (TPM) (DeBoever et al., 2017).
Generation of scRNA-Seq Data
To capture the full spectrum of heterogeneity among the iPSC-
CVPCs, we selected eight samples with variable percentage of
cTnT (42.2%–95.8%). After removing proliferating cells and dou-
blets, we obtained 34,905 cells.
CIBERSORT
Expression levels of the top 50 genes overexpressed in each of the
three cell populations (total 150 genes)were used as input forCIBER-
SORT (Newman et al., 2015) to calculate the relative distribution of
the three cell populations for the 180 iPSC-CVPC samples at day 25.
Characterizing Transcriptional Similarities of iPSCs,
iPSC-CVPCs, and GTEx Adult Tissues
Weperformed PCAof RNA-seq on 184 iPSCs, 180 iPSC-CVPCs, and
1,072 RNA-seq samples from GTEx.
Determining Optimal CM/EPDC Ratio Estimates from
CIBERSORT to Define iPSC Cardiac Fates
To obtain the optimal threshold, we conducted a series of differen-
tial expression analyses on 15,228 autosomal genes in the 184 iPSC
lines (147 completed and 37 terminated) considering the ratio of
population frequencies at ten thresholds. The 30:70 (CM/EPDC)
ratio resulted in the highest number of differentially expressed
genes (84 genes with Storey q value <0.1, t test), which is substan-
tially greater than random expectation. Thus, we grouped the 184
iPSC lines into: (1) those that have CM fates, i.e., produced iPSC-
CVPC with R30% population 1; and (2) those that have EPDC
fates, i.e., produced iPSC-CVPC with >70% population 2.
Comparing the Number of Differentially Expressed
Genes with Random Expectation
To determine whether the number of significantly differentially
expressed genes was higher than expected by chance, we shuffled
the assignments of the 184 iPSC RNA-seq samples to differentia-
tion fate (125 CM and 59 EPDC) 100 times.
Contribution of 91 Signature Genes in iPSCs to
Determination of Cardiac Fate
For each of the 91 signature genes, we built a GLMwith the expres-
sion of the gene as input and the differentiation outcome (e.g., per-
centage of population 1) as output using a logit link function. To936 Stem Cell Reports j Vol. 13 j 924–938 j November 12, 2019understand the cumulative contribution of all 91 signature genes
on cardiac differentiation fate, we built a GLM with an L1 norm
penalty using the expression of all 91 genes as input and the differ-
entiation outcome as output. To avoid overfitting the model, we
used a 10-fold cross-validation.Detecting Associations between Genetic Background
and Differentiation Outcome
We obtained genotypes for 8,620,159 biallelic SNPs and short in-
dels with allelic frequency >5% in the iPSCORE collection. Geno-
types were obtained for each SNP in all individuals using bcftools
view (Li, 2011). Linear regression was used to calculate the associa-
tions between the genotype of each variant and differentiation
outcome (percent CM population in the iPSC-CVPCs), using pas-
sage at monolayer and sex as covariates.GSEA Using the MSigDB Collection
We performed GSEA using the R gage package (Luo et al., 2009) on
all MSigDB gene sets (Subramanian et al., 2005). False discovery
rate correction was performed independently for each collection.
The normalized mean expression difference between iPSCs that
differentiated to CMs and iPSCs that differentiated to EPDCs was
used as input for GSEA.Associations between iPSC and Subject Features and
Differentiation Outcome
A GLM was built in R using age, sex, ethnicity, age, and passage of
the iPSCs at day 0 of differentiation as input and differentiation
outcome as output (0 = EPDCs; 1 = CMs).Identifying X Chromosome Inactivation in Female
iPSCs and iPSC-CVPCs
To analyze X chromosome inactivation, we used 113 female iPSCs,
of which 87 where CM-fated and 26 were EPDC-fated. We called
ASE in RNA-seq from iPSC and iPSC-CVPCs as previously
described (DeBoever et al., 2017). Genes lying in X chromosome
pseudoautosomal (PAR) regions (PAR1: 60,001–2,699,520; PAR2:
154,931,044–155,260,560) were removed from analysis. We
defined the strength of ASE for each gene as the fraction of RNA
transcripts that were estimated to originate from the allele with
higher expression (referred to as AIF).Validation of Findings in Yoruba iPSC Set
The Yoruba iPSCs (Banovich et al., 2018) were generated fromLCLs
using episomal reprogramming. Differentiation was performed us-
ing a small-molecular method and iPSC-CMs were harvested on
days 31 or 32. Fifteen lines successfully generated iPSC-CMs and
24 were terminated on or before day 10. We downloaded RNA-
seq for 34 of the Yoruba iPSC and 13 iPSC-CM samples from the
Gene Expression Omnibus (GEO: GSE89895) as well as 297 sam-
ples from 19 distinct iPSCs in a time-course experiment (days
0–15) performed on the same Yoruba iPSC samples (Strober et al.,
2019). RNA-seq was aligned using STAR, and gene expression was
quantified using the RSEM package and normalized to TPM. The
RNA-seq for the 13 Yoruba iPSC-CMs and from all time-course
time points were analyzed using CIBERSORT, similar to the
iPSCORE samples.
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